- Oxford Biomedica
- 07 October 2025 10:55:12
Source: Sharecast
Oxford Biomedica said the deal includes a 75,000 square foot GMP facility and associated assets, which will be integrated into its Oxford Biomedica Solutions business. The site has previously supported commercial and clinical production for multiple viral vector platforms, including adeno-associated virus, lentiviral and adenoviral vectors.
The FTSE 250-listed firm stated the acquisition would enhance its capacity and capabilities in the US, supporting long-term growth and client demand, and was expected to complete in Q425, subject to customary closing conditions.
Chief executive Frank Mathias said: "This acquisition is a major milestone in OXB's evolution as a global, innovation-led CDMO partner of choice. The FDA approved facility in North Carolina adds commercial-scale US manufacturing capabilities, accelerating OXB's ability to meet growing demand from existing clients while supporting new business opportunities.
"It significantly expands our footprint in the world's largest cell and gene therapy market and enhances our ability to support clients globally across all major viral vector types and stages of development, particularly those in the AAV field. By expanding our capabilities in the US, we're executing on our growth strategy and unlocking long-term value for both clients and shareholders."
Oxford Biomedica added that the acquisition would be funded from existing cash resources and was expected to be earnings accretive from 2026.
As of 1055 BST, Oxford Biomedica shares were down 0.53% at 633.61p.
Reporting by Iain Gilbert at Sharecast.com
